Health Institute Carlos III
If you are the contact person for this centre and you wish to make any changes, please contact us.
PhD in Pharmacy, Professor of Human Physiology at the University of Navarra, member of the CIBER Physiopathology of Obesity, Carlos III Health Institute and IDISNA (Navarra)
Head of the Influenza and other Respiratory Virus Surveillance Group of the National Epidemiology Centre.
Researcher at the Reference and Research Laboratory in Mycology, National Microbiology Centre, Instituto de Salud Carlos III
Senior Scientist at the Health Institute Carlos III
Researcher in social epidemiology, public health and biostatistics
Co-director of the Reference Unit on Climate Change, Health and Urban Environment of the Instituto de Salud Carlos III and scientific coordinator of the Observatory on Health and Climate Change
Senior Scientist at the Special Pathogens Research and Reference Laboratory of the National Microbiology Centre of the Carlos III Health Institute
Director and Research Scientist at the Institute for Rare Diseases Research (IIER), Carlos III Health Institute (ISCIII)
Researcher at the National Center for Microbiology - Carlos III Health Institute
Senior scientist at the Reference Laboratory for Influenza and Respiratory Viruses of the National Microbiology Centre.
In Spain, since 13 January, the booster vaccination against covid-19 has been recommended for the general adult population. 78.8 % of those over 50 and 88.9 % of those over 60 have already had it, said the Minister of Health yesterday. If those who are missing have doubts, here we try to solve them.
The first solid work on the ability of vaccines to stop infection with the omicron variant, which has just been published, reinforces the need for a third dose. Experts recall, however, that the aim of vaccines was never to stop infection, but to prevent severe disease. We summarize what is known so far about it.
A survey conducted by the COSMO-Spain team to find out the reasons why some people have not yet been vaccinated showed that most of them fear that vaccines are unsafe and their side effects. These results highlight the importance of rigorous communication of drugs that are considered safe and effective by all studies and agencies.
In the last few days, data, preprints, press releases and even graphs have started to arrive via social media showing how neutralising antibodies against the omicron variant behave. These studies are preliminary and we will have to wait and see how these lab data translate into the real world.
A new variant of the coronavirus causing COVID-19 has been identified in South Africa, with numerous mutations present in other variants, including Delta. Variant B.1.1.529, as it is now called, appears to be spreading rapidly in South Africa. Attached is the rapid reaction of three Spanish researchers with expertise in genomic surveillance.
A study of more than 700,000 people in Sweden analysed the effectiveness of the heterologous schedule, combining the AstraZeneca vaccine with another dose of a messenger RNA vaccine, with the traditional homologous schedule, consisting of two doses of AstraZeneca. The results showed increased protection against SARS-CoV-2 infection when two different vaccines were combined.